This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
UBE2J1 inhibits colorectal cancer progression by promoting ubiquitination and degradation of RPS3
Oncogene Open Access 26 December 2022
-
Utidelone inhibits growth of colorectal cancer cells through ROS/JNK signaling pathway
Cell Death & Disease Open Access 01 April 2021
-
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway
Journal of Hematology & Oncology Open Access 07 November 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Cassidy, S., Syed, B. Colorectal cancer drugs market. Nat Rev Drug Discov 16, 525–526 (2017). https://doi.org/10.1038/nrd.2017.59
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.59
This article is cited by
-
Discovery of a nitroaromatic nannocystin with potent in vivo anticancer activity against colorectal cancer by targeting AKT1
Acta Pharmacologica Sinica (2024)
-
UBE2J1 inhibits colorectal cancer progression by promoting ubiquitination and degradation of RPS3
Oncogene (2023)
-
Utidelone inhibits growth of colorectal cancer cells through ROS/JNK signaling pathway
Cell Death & Disease (2021)
-
A novel protein encoded by circFNDC3B inhibits tumor progression and EMT through regulating Snail in colon cancer
Molecular Cancer (2020)
-
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway
Journal of Hematology & Oncology (2020)